Nicotine receptor partial agonists for smoking cessation.

Journal article

BACKGROUND: Nicotine receptor partial agonists may help smokers to quit by a combination of maintaining moderate levels of dopamine to counteract withdrawal symptoms (acting as an agonist) and reducing smoking satisfaction (acting as an antagonist). Varenicline was developed as a nicotine receptor partial agonist from cytisine, a drug widely used in central and eastern Europe for smoking cessation. The first trial reports of varenicline were released in 2006, and further trials are underway....

Expand abstract

Authors: Cahill, K; Stead, L; Lancaster, T

• Publication status: Published
• Journal: Cochrane database of systematic reviews
• Volume: 12
• Issue: 1
• Pages: CD006103
• Publication date: 2007-01-01
• DOI: 10.1002/14651858.cd006103.pub2
• EISSN: 1469-493X
• ISSN: 1469-493X
• Language: English
• Keywords: Quinolizines; Quinoxalines; Nicotine; Smoking Cessation; Azocines; Benzazepines; Randomized Controlled Trials as Topic; Alkaloids; Humans; Nicotinic Agonists